Michael J. Warwick

Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.

Fergus McTaggart, Linda K. Buckett, Robert G. Davidson et al. · The American Journal of Cardiology · 2001 · 415 citations

Medicine, Pharmacology, Pharmacotherapy +8

An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers

Paul Martin, Aaron Dane, Dennis W. Schneck et al. · Clinical Therapeutics · 2003 · 104 citations

Pharmacy, Pharmacokinetics, Pharmacology +6

The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics

Paul Martin, Dennis W. Schneck, Aaron Dane et al. · Current Medical Research and Opinion · 2008 · 49 citations

Pharmacy, Pharmacokinetics, Pharmacology +11

Quantification of the N-desmethyl metabolite of rosuvastatin in human plasma by automated SPE followed by HPLC with tandem MS detection

Caroline K Hull, Paul Martín, Michael J. Warwick et al. · Journal of Pharmaceutical and Biomedical Analysis · 2004 · 29 citations

Life Sciences, Pharmaceutical Analysis, Pharmacology +16